Cardiac Profiles of Liposomal Anthracyclines: Greater Cardiac Safety versus Conventional Doxorubicin?

Cancer

Volumn 100, Issue 10, 2004, Pages 2052-2063

  Theodoulou, Maria ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anthracyclines; Breast neoplasms; Doxorubicin; Drug toxicity; Liposomes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; LIPOSOMAL ANTHRACYCLINE DERIVATIVE; LIPOSOMAL DAUNORUBICIN; LIPOSOME; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BOLUS INJECTION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOXICITY; ENCAPSULATION; HUMAN; KAPOSI SARCOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HEART; HEART DISEASES; HUMANS; LIPOSOMES; NEOPLASMS; POLYETHYLENE GLYCOLS; RISK FACTORS; SAFETY;

EID: 2342488025     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20207     Document Type: Review

References (54)

1. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263-302.
2. Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Lee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 3rd edition. Stamford. CT: Appleton & Lange, 1997:2403-2465.
3. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24:903-920.
4. Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol. 2002;85:18-31.
5. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs. 1997;54(Suppl 4):1-7.
6. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
7. Wigler N, O'Brien M, Rosso R, et al. Reduced cardiac toxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin (CAELYX™/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, Florida.
8. Pharmacia & Upjohn Company. Adriamycin RDF®/Adriamycin PFS® (doxorubicin hydrochloride for injection) [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company, 2002.
9. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toicity. Cancer Treat Rev. 1993;19:197-228.
10. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
11. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
13. Ewer MS, Benjamin RS. Cardiac complications of cancer treatment. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors. Cancer medicine. 5th edition. Ontario: BC Decker Inc., 2002:2330-2339.
14. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139.
15. Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol (R Coll Radiol). 2000;12:146-152.
16. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 1999;3:145-159.
17. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-127.
18. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333-1340.
19. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-1332.
20. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs. 1997;54(Suppl 4):15-21.
21. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target. 1996;4:129-140.
22. Gilead Sciences, Inc. DaunoXome® (daunorubicin citrate liposome injection) [package insert]. San Dimas, CA: Gilead Sciences, Inc., 2000.
23. Elan Pharmaceuticals. Myocet™ (doxorubicin HCl liposome injection) product information. Princeton: Elan Pharmaceuticals, 2000.
24. Ortho Biotech Products. Doxil® (doxorubicin HCl liposome injection) [package insert]. Raritan: Ortho Biotech Products L.P., 2001.
25. Harris L, Batist G, Belt R, et al. for the TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36.
26. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-1454.
27. Levine AM, Tulpule A, Espina BM, et al. A Phase I/II trial of liposomal doxorubicin (TLC D-99, Myocet) with cyclophosphamide, vincristine, and prednisone in newly diagnosed aggressive non-Hodgkins lymphoma [abstract 1133]. Proc Am Soc Clin Oncol. 2002;21:284a.
28. Tulpule A, Espina BM, Dharmapala D, Boswell WD, Welles L, Levine AM. Treatment of newly diagnosed AIDS-related lymphomas with liposomal doxorubicin (TLC-D99, Myocet) combined with cyclophosphamide, vincristine, and prednisone: results of a Phase I/II trial [abstract 1135]. Proc Am Soc Clin Oncol. 2002;21:285a.
29. Theodoulou M, Campos SM, Batist G, et al. TLC D-99 (D, Myocet™) and Herceptin™ (H) is safe in advanced breast cancer: final cardiac safety and efficacy analysis. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, Florida.
30. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8:431-450.
31. Gabizon AA, Muggia FM. Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors. In: Woodle MC, Storm G, editors. Long circulating liposomes: old drugs, new therapeutics. New York: Springer-Verlag and Landes Bioscience, 1998:165-174.
32. Working PK, Dayan AD. Pharmacological-toxicological expert report. CAELYX (stealth liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15:751-785.
33. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9:711-716.
34. 2. Ann Oncol. 2000;11:1029-1033.
35. Gabizon AA, Lyass O. Cardiac safety of pegylated liposomal doxorubicin demonstrated by endomyocardial biopsy in patients with advanced malignancies. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, Illinois.
36. Mustafa MH. Decreased risk of cardiotoxicity with long-term use of Doxil®/Caelyx™ at high lifetime cumulative doses in patients with AIDS-related Kaposi's sarcoma (KS) [abstract 2915]. Proc Am Soc Clin Oncol. 2001;20:291b.
37. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995;13:996-1003.
38. Gill PS, Wernz J, Scadden DT, et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
39. Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC. Liposomal daunorubicin in advanced Kaposi's sarcoma: a Phase II study. Clin Oncol (R Coll Radiol). 1993; 5:367-371.
40. 2 of liposomal encapsulated daunorubicin (DaunoXome®) [abstract 761]. Proc Am Soc Clin Oncol. 1997;16:217a.
41. O'Byrne KJ, Thomas AL, Sharma RA, et al. A Phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer. 2002;87:15-20.
42. Fassas A, Buffels R, Anagnostopoulos A, et al. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a Phase I-II study. Br J Haematol. 2002; 116:308-315.
43. Pratt CB, Ransom JL, Evans WE. Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;62:1381-1385.
44. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62:200-208.
45. Lowis S, Lewis I, Elsworth A, Ablett S, Robert J, Frappaz D. Cardiac toxicity may limit the usefulness of liposomal daunorubicin (DaunoXome): results of a phase I study in children with relapsed or resistant tumours - a UKCCSG/SFOP study [abstract 435]. Proc Am Soc Clin Oncol. 2002;21:109a.
46. Lenaz L, Page JA. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111-120.
47. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol. 1999;17:1435-1441.
48. Billingham M, Bristow M. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp. 1984;3:71-76.
49. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
50. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
51. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83.
52. Trigo J, Climent MA, Lluch A, et al. Liposomal doxorubicin (Myocet®) in combination with Herceptin® and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC): a Phase II study. Poster presented at the 26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003, San Antonio, Texas.
53. Wolff AC, Bonetti M, Sparano JA, Wang M, Davidson NE, on behalf of the Eastern Cooperative Oncology Group. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer: preliminary results of ECOG 3198. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, Illinois.
54. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(Suppl 2):17-24.